yellowhoard's  Instablog

Send Message
There are only two things in this world that I can't stand...people who are intolerant of other people's cultures, and the Dutch.
  • Me So Ronry 15 comments
    Aug 4, 2009 6:46 PM

    Now that Kim Jung Ill has been paid off for taking hostages and releasing them to Hillary's husband, I thought Trey Parker's musical homage to the Dear Leader was appropriate today.



Back To yellowhoard's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (15)
Track new comments
  • ScroogeMcduck
    , contributor
    Comments (511) | Send Message
    Thanks for the laugh hoard
    4 Aug 2009, 09:09 PM Reply Like
  • Swashbuckler
    , contributor
    Comments (715) | Send Message
    Enjoyed the clip. Clinton gave Kim Jong mentally ILL the money, the material, and the technology for nukes. Then Madelaine Albright said later "He tricked us." So maybe the hostage release was a token of appreciation to Bill.
    4 Aug 2009, 09:31 PM Reply Like
  • PainfullyAware
    , contributor
    Comments (1086) | Send Message
    He He He He.


    Maybe They Can Get In Some Golf.
    5 Aug 2009, 02:50 AM Reply Like
  • yellowhoard
    , contributor
    Comments (1500) | Send Message
    Author’s reply » That would be funny!


    Clinton and Kim Jung Ill in a golf cart. I'd pay good money for that poster.
    5 Aug 2009, 08:00 AM Reply Like
  • modern pragmatist
    , contributor
    Comments (19) | Send Message
    Which one would win, or would it be a tie with them both getting a 1.
    5 Aug 2009, 09:54 AM Reply Like
  • optionsgirl
    , contributor
    Comments (5202) | Send Message
    Wednesday August 5, 2009, 11:33 am EDT
    Buzz up! 0
    Companies: AstraZeneca PlcBioCryst Pharmaceuticals Inc.Dynavax Technologies Corporation
    Vaccine stocks were mixed mid-week, some on flu-related news, others not.


    Related Quotes
    Symbol Price Change
    AZN 45.84 -0.90


    BCRX 9.22 -0.38


    DVAX 1.79 -0.16


    HEB 2.12 -0.04


    INO 2.33 -0.16


    After the bell yesterday, Dynavax Technologies (NASDAQ: DVAX - News) announced second-quarter net income of $4.1 million or 10 cents a share on revenues totaling $35.2 million. The results were a significant improvement over the same period last year, during which the company lost -$6.1 million or 15 cents a share. Just prior to releasing quarterly performance figures, Dynavax announced that it met with the FDA to discuss plans to resume the development of a hepatitis B vaccine. The company also has Phase 1 clinical stage programs underway for two other hepatitis therapies. The stock has pared its gains throughout the session, but remains ahead by 7%. Some of its peers are up big on the day, while much of the sector remains in negative territory.


    As a whole, the Swine and Bird Flu Stocks Index is up by 3.2% today. It is currently outperforming the S&P 500 by 18.2% over the last month.


    Inovio Biomedical (AMEX: INO - News) was added to the Index last week when its swine flu vaccine showed 100% protection against the virus in animal studies. Today it too is moving on news unrelated to the H1N1 virus. Announced early this morning, the company has data representing what it believes to be the first human demonstration of significant and persistent antibody response stimulated by the Inovio's electroporation technology. The DNA vaccine is aimed to combat tumor cells by boosting T-cell response. Dr. Christian Ottensmeier, head of the study, said, "this data supports optimism for use of this next-generation vaccine modality as a strategy against infections and cancer." Inovio shares are adding 22% to their huge, 236% one-month rally.


    Novavax (NASDAQ: NVAX - News) is up 13% ahead of Friday's earnings report. Analysts are expecting the company to report an -11-cent loss per share. According this morning's report by the Associated Press, the company synthesized a version of the swine flu virus that cannot replicate, which has potential for use in a vaccine. According to the AP, Novavax boasted that the virus-like particle was generated only 11 weeks after receiving the gene sequence from the Centers for Disease Control, a feat that the company believes shows its abilities under pandemic pressure.


    Sanofi-Aventis (NYSE: SNY - News) is among the day's laggards, down by over -2%. It is hanging onto a 1% over the last week. Meanwhile, Novartis (NYSE: NVS - News) and AstraZeneca (NYSE: AZN - News) are up by 4.5% and 1.5% respectively in the past five days.


    Small-cap favorite Hemispherx Biopharma (AMEX: HEB - News) is up by 6% today. It remains the only stock in the Index to suffer losses over the last month, down -15%. Inovio and BioCryst (NASDAQ: BCRX - News) are laggards over the last week.


    As of this writing, the Swine Flu Stocks Index is one of the top-10 performing tickerspy Indexes over the last week, up 30%.


    Investors can follow the Swine and Bird Flu Stocks Index and view related performance charts and metrics at


    Fun and informative, is a free investing website where you can track multiple stock portfolios and compare against 250 proprietary Indexes tracking themes from nanotech to agriculture to precious metals. Best of all, lets you spy on the portfolios of nearly 3,000 Wall Street institutions and hedge funds and see graphs of their performance. Try today and find out how you stack up against investing legends like Warren Buffett!


    Buzz up! 0
    Related Headlines


    Canadian Solar, EnerNOC and Orthovita lead small-cap volume in pre-market -
    Seasonal flu vaccine shipping early, demand up - AP
    AIG, American Axle, Whole Foods, EA are big movers - AP
    It's Not All Swine Flu for Vaccine Stocks - Indie Research
    Novavax says it synthesized swine flu for vaccine - AP
    Related Blog Headlines


    FDA Calendar Updates: Covidien, Dynavax, Nuvo Research - at Seeking Alpha
    Another Cholesterol Drug to Join the U.S. Market - at The Wall Street Journal Online
    New Diabetes Drug Could Give Januvia Stiff Competition - at Seeking Alpha
    Inovio Shares Surge on News of Experimental Flu Vaccine Approach - at Seeking Alpha
    Nycomed/Solvay: Is Europe's Pharma Sector Getting Its M&A Groove On? - at The Wall Street Journal Online
    Top Stories


    Former AIG CEO Greenberg to Pay $15 Million To SEC - at CNBC
    Stocks fluctuate after jobless claims report - AP
    Judge sets hearing on BofA-SEC settlement - AP
    Sluggish July sales show tight-fisted U.S. consumers - AP
    Senate to consider $2B 'clunkers' refill - AP
    Related Message Boards


    AstraZeneca Plc
    BioCryst Pharmaceuticals Inc.
    Dynavax Technologies Corporation
    Hemispherx Biopharma, Inc.
    Inovio Biomedical Corporation
    Novavax, Inc.
    Novartis AG
    Sponsored Links


    The TRUTH About Working From Home
    Can The Average Person Make A Living Working From Home? We Report.
    Breaking News: "$1,183/Week From HOME!"
    "Work From Home STARTER KITS!" Make It Easy For The Average Person.
    How to Reduce Your Debt
    Improve Your Personal Finances. How to Budget & Manage Your Money.
    Do You Know Your Credit Score?
    Want a New Car or Home? First Get a 100% Free Credit Report Right Now.


    Tech Ticker Recent Posts


    World's Smartest Economists Off to Fish and Drink in Maine - Henry Blodget
    Has Cisco's John Chambers Lost His Mind? - Henry Blodget
    How OpenTable Went Public – and Why Others Aren't - Sarah Lacy
    View More »
    Subscribe to Topics


    Top Stories
    Add Alert
    AZN Headlines
    Add Alert
    BCRX Headlines
    Add Alert
    DVAX Headlines
    Add Alert
    6 Aug 2009, 11:39 AM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (6282) | Send Message
    Are you using the McClellan to indicate your entry point on SDS?
    6 Aug 2009, 11:57 AM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (6282) | Send Message
    Great info OG!
    6 Aug 2009, 12:01 PM Reply Like
  • optionsgirl
    , contributor
    Comments (5202) | Send Message
    Freya- if you want to add to your nvax position, why aren't you buying calls? Are they pricey? I haven't priced them but I was thinking maybe some in the money calls for jan 2010 might do the trick. Have you priced em?
    6 Aug 2009, 12:51 PM Reply Like
  • Mayascribe
    , contributor
    Comments (11198) | Send Message
    Funny stuff, Yellow!
    10 Aug 2009, 11:01 AM Reply Like
  • optionsgirl
    , contributor
    Comments (5202) | Send Message
    Everyone has different investment styles, but if you want to grow more comfortable with the idea, a great free resource is: www.schaeffersresearch.../
    10 Aug 2009, 11:43 AM Reply Like
  • optionsgirl
    , contributor
    Comments (5202) | Send Message
    Do you have an opinion on DVAX?
    10 Aug 2009, 11:44 AM Reply Like
  • optionsgirl
    , contributor
    Comments (5202) | Send Message
    CIT looks like they are going bankrupt.
    11 Aug 2009, 12:08 PM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (6282) | Send Message
    Thank you for the reference to Schaeffer OG.
    11 Aug 2009, 12:46 PM Reply Like
  • optionsgirl
    , contributor
    Comments (5202) | Send Message
    i'm signed up to get updates twice a day. it's wonderful. Schaeffer also wrote a great book on options investing, in the mid 90's. it's still in print and cheap- maybe ten bucks. wonderful stuff. although options have changed, there is still a lot of good material that is as timely now as it was then!


    On Aug 11 12:46 PM User 283977 wrote:


    > Thank you for the reference to Schaeffer OG.
    11 Aug 2009, 01:23 PM Reply Like
Full index of posts »
Latest Followers


  • I'm back.
    Apr 29, 2015
  • Welcome to stagflation!
    Dec 15, 2009
  • Is it just me or are the financials rolling over?
    Dec 3, 2009
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.